For SSCP analysis, 2 ur, of PCR product were added to 2 ul, of distilled water and mixed with 4 'ul. of denaturing buffer (95% formarnide, 0.05% xylene cyanol and 0.05% bromophenol blue) . The samples were heated to 95°C for 5 min and immediately placed in an ice/water bath and maintained at the temperature required for subsequent electrophoresis. Samples were run on the Phastxystem" (Pharmacia Biotech, Uppsala, Sweden) using 20% precast polyacrylamide gels and native buffer strips at 11°C and 250 V, 2.5 rnA, for 550 Vh. Duplicate samples were run on each half of the same gel; only one-half of which was stained using the Pharmacia Biotech silverstaining protocol.
Mutant SSCP bands were visualized on the silver-stained portion of the gels, and corresponding acrylamide slices were taken from the paired, unstained gel half using a sterile scalpel blade (equal-sized slices of acrylamide from adjacent lanes of the same gel that contained no DNA were used as nega- 
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INTRODUCTION
A variety of mitochondrial DNA (mtDNA) mutations have been associated with human disease (9) . The search for such mutations is confounded by the significant amount of normal polymorphism within mtDNA. However, severely .or moderately deleterious mtDNA defects are characteristically heteroplasmic (i.e., both mutant and wild type are present in a single cell), and interest therefore centers on the identification of such defects (6) .
The ratio of wild-type to mutant mtDNA can vary considerably from patient to patient and within specific tissues from the same individual (5) . In adults, the highest level of mutant mtDNA is usually observed in muscle and brain" Since these tissues are poorly accessible, recent work has focused on the detection of pathogenic mtDNA defects in peripheral blood samples. Unfortunately, the level of heteroplasmy in peripheral leukocytes may be low (<10%), and mutation screening techniques such as restriction fragment length polymorphisms (RFLPs) or direct DNA sequencing may fail to detect the minor mtDNA population. A method is therefore required to enrich heteroplasmic mtDNA variants from peripheral blood samples.
We have previously reported the use of polymerase chain reaction singlestranded conformational polymorphism analysis (PCR-SSCP) for the detection of pathogenic heteroplasmic mtDNA mutations, including those associated with mitochondrial encephalopathies and diabetes (8) . The use of precast polyacrylamide gels and a microprocessor-controlled electrophoresis system allows the rapid and reliable detection of low-level heteroplasmic mutations (z l %) (7) . SSCP analysis is not specific for individual mutations, since the same band pattern may be produced by different DNA mutations; sequencing of SSCPs is required . Here we report a nonradioactive method for mutation detection based on SSCP-PCR enrichment followed by automated fluorescence-based DNA sequencing. The technique is based on a method previously reported for germline mutation analysis (1). The unique aspect of this report relates to its application in the characterization of low-level heteroplasmic mutations in mtDNA.
MATERIALS AND METHODS
mtDNA was extracted from peripheral blood samples (using a Nucleon'Y DNA extraction kit; Scotlab, Glasgow, Scotland, UK) obtained from two subjects with myoclonic epilepsy and redragged fibers (the MERRF syndrome) on muscle biopsy. These subjects had a point mutation in the mitochondrial tRNAlys gene at nucleotide 8344, and the levels of heteroplasmy in peripheral blood samples were 80% and 14% (Figure 1) .
A 249-bp region containing this gene was amplified in a 30-cycle PCR, employing a forward primer spanning nucleotides 8196-8215 and a reverse primer spanning nucleotides 8445- tive controls). Sterile deionized water (25~L) was added to each acrylamide slice in a sterile tube and incubated for I h at 37°C. After centrifugation at 13 OOOx g for 2 min, 5~L of the supernatant were added to a PCR to give a final volume of 25~L. The PCR products were purified using the Wizard" PCR Prep kit (Promega, Southhampton, England, UK) and 300 ng of DNA used in an Applied Biosystems Taq Dyefreoxyl'" Terminator Cycle sequencing reaction (Perkin-Elmer/Applied Biosystems Division [PE/ABI], Warrington, England, UK). Samples were run on a Model 373A Automated DNA Sequencing System (PE/ABI).
To assess the sensitivity of SSCP analysis and automated fluorescencebased DNA sequencing in the detection of low-level heteroplasmic mutations, the PCR product obtained from the subject known to have 80% mutation (Figure 1, lane 3) was diluted with various amounts of normal control PCR product (Figure 1, lane 1) . Ratios of mutant:normal PCR product ranging from 40% mutant:60% normal to 0% mutant: 100% normal were produced (Figure 2 ). Mutant and normal PCR products were adjusted to the same 2 3 4 5 6 concentration before mixing. The percentage of heteroplasmy in samples was estimated by scanning the silver-stained SSCP gel (Figure 1 ) with a Model GS-670 Imaging Densitometer (Bio-Rad, Hemel Hempstead, Herts, England, UK). Data were analyzed using Bio-Rad Molecular Analyst software.
RESULTS AND DISCUSSION
SSCP analysis , using the PhastSystern with silver staining, clearly distinguished the 8344-bp mutation to a level of 5% heteroplasmy. The sample having 1% heteroplasmy was just visible on direct inspection of the gel (Figure 2 ). This sensitivity is greater than standard PCR-RFLP analysis on ethidium bromide-stained agarose gels, using mismatch primers to create a unique restriction site in mutant PCR products (10), which could only detect the mutation in samples with heteroplasmy >30% (results not shown). The sensitivity of PCR-RFLP analysis can be enhanced, by using radioactive labeling of PCR products, to a level similar to that seen in our silver-stained PhastGels® (3).
Direct automated sequencing of the heteroplasmic samples only demonstrated the A to G base substitution in the samples with a level of heteroplasmy >20%. Generally, base substitution peaks in samples with between 20% and 30% mutant present could not be clearly distinguished above the level of background. However, a small underlying G peak could have been identified in a patient sample with 14% mutant present ( Figure 3B ). A comparable level on the limit of detection, between 10% and 25%, was also observed during the sequence analysis of heterogeneous viral populations (4) .
The level of background, seen as secondary peaks, and the variable peak intensities characteristic of automated fluorescence-based DNA sequencing of PCR products make it almost impossible to detect unknown heteroplasmic mutations (Figure 3 ). Despite this, we and others (2) have found that the patterns of the sequencing traces in different samples are faithfully reproduced every time the same gene region procedure to screen for novel heteroplasmic mutations in other mtDNA genes. The technique could also be adapted to identify other heterogeneous mutations in chromosomal genes, e.g., mosaic mutations from skin biopsies or oncogene mutations in mixed populations of normal and cancer cells. Such defects can be present in very small amounts, and automated sequencing may fail to identify low-level heterozygous base substitutions or deletions.
In conclusion, the method of SSCPP CR enrichment of low-level heteroplasmic mutations will enable the identification and characterization of novel and potentially pathogenic mtDNA defects. is examined (Figure 3 ). Excision and re-amplification by PCR of the mutant SSCP band from the patient sample with 14% heteroplasmy (Figure 1, lane 2) enabled the A to G base substitution to be clearly seen on the automated sequence data as a novel peak with no evidence of a secondary signal ( Figure 3C ). In fact, as long as the variant SSCP band was just visible on the silver-stained gel, it was possible to excise, re-amplify and obtain good sequence data for the sample. This procedure was successful up to the limit of 1% heteroplasmy.
The SSCP-PCR enrichment process that we describe will be of significant value for the detection of other known heteroplasmic mtDNA mutations, especially those occurring at low levels in peripheral blood samples , e.g., the 3243-bp mtDNA mutation associated with diabetes and deafness . As the entire mitochondrial sequence is known, it will be possible to use this
